Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide-Induced Weight Reduction in Obese Populations
NCT06825793Not yet recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Open-label trial of semaglutide in obesity (2 arms), sponsored by Beijing Chaoyang Hospital. Primary endpoints: Body weight at 28 weeks and Gut microbiota abundance and diversity at 28 weeks. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06825793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825793.